Bunn P A, Kelly K
Division of Medical Oncology, University of Colorado Cancer Center, Denver 80262, USA.
Semin Oncol. 1995 Jun;22(3 Suppl 6):53-63.
The cure rate for lung cancer remains low (13%) primarily due to early systemic spread and the inability to cure systemic disease. These facts have led to pessimism regarding the role of chemotherapy, especially in non-small cell lung cancers. However, recent randomized trials demonstrated that chemotherapy significantly prolongs survival in advanced (stages IIIB and IV) and locally advanced (stages IIIA and IIIB) non-small cell lung cancers. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is an active agent in both non-small and small cell lung cancers, producing objective response rates as high as any other active agent. Early combination studies show even higher response rates when paclitaxel is combined with cisplatin or carboplatin. Ultimately, randomized trials will be needed to define the optimal use of paclitaxel and other recently developed new agents in lung cancer.
肺癌的治愈率仍然很低（13%），主要原因是早期发生全身转移以及无法治愈全身性疾病。这些事实导致人们对化疗的作用持悲观态度，尤其是在非小细胞肺癌中。然而，最近的随机试验表明，化疗可显著延长晚期（IIIB期和IV期）和局部晚期（IIIA期和IIIB期）非小细胞肺癌患者的生存期。紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）在非小细胞肺癌和小细胞肺癌中都是一种活性药物，其客观缓解率与任何其他活性药物一样高。早期的联合研究表明，当紫杉醇与顺铂或卡铂联合使用时，缓解率更高。最终，需要进行随机试验来确定紫杉醇和其他最近开发的新型药物在肺癌中的最佳使用方法。
